- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.04. | Aura Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Aura Biosciences GAAP EPS of -$1.93 | 1 | Seeking Alpha | ||
| 27.03. | Aura Biosciences Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 27.03. | Recap: Aura Biosciences Q4 Earnings | 2 | Benzinga.com | ||
| 27.03. | Aura Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 27.03. | Aura Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Aura Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | 88 | Business Wire | BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the... ► Artikel lesen | |
| 08.01. | Aura Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.12.23 | Arix Bioscience PLC: Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial | 501 | Dow Jones News | DJ Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
Arix Bioscience PLC (ARIX)
Portfolio Company Aura Biosciences Announces First Patient Dosed... ► Artikel lesen | |
| 13.11.23 | Arix Bioscience PLC: Portfolio Company Aura Biosciences Announces Closing of USD99 million Public Offering of Common Stock | 586 | Dow Jones News | DJ Arix Bioscience PLC: Portfolio Company Aura Biosciences Announces Closing of USD99 million Public Offering of Common Stock
Arix Bioscience PLC (ARIX)
Correction: Portfolio Company Aura Biosciences... ► Artikel lesen | |
| 10.11.23 | Aura Biosciences director David Johnson buys common shares worth ~$1.44M | 3 | Seeking Alpha | ||
| 10.11.23 | Aura Biosciences GAAP EPS of -$0.48 | 3 | Seeking Alpha | ||
| 09.11.23 | Aura Biosciences Inc reports results for the quarter ended in September - Earnings Summary | 3 | Reuters | ||
| 09.11.23 | Aura Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.11.23 | Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights | 332 | Business Wire | BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology... ► Artikel lesen | |
| 08.11.23 | Aura Biosciences Inc.: Aura Biosciences to Participate in Upcoming Investor Conferences | 310 | Business Wire | Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced... ► Artikel lesen | |
| 07.11.23 | Why Aura Biosciences Stock Hit A New 52-Week Low Today | 3 | Benzinga.com | ||
| 07.11.23 | Aura Biosciences slides on pricing stock offering | 1 | Reuters | ||
| 07.11.23 | Aura Biosciences announces pricing of public offering of common stock | 1 | Seeking Alpha |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,580 | -3,07 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,850 | 0,00 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,839 | 0,00 % | Collaboration advancing new sourdough strain: Ginkgo Bioworks working with Italian baking ingredients company | ||
| BEAM THERAPEUTICS | 22,740 | 0,00 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 0,990 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA | Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer
Overall survival results from the randomized HR+/HER2- metastatic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,940 | 0,00 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
| ARCTURUS THERAPEUTICS | 26,980 | -3,40 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,866 | 0,00 % | Assertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial Results | Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,660 | 0,00 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,710 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,040 | -1,11 % | How Vir found the one: CEO Marianne De Backer | ||
| VERVE THERAPEUTICS | 6,580 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,260 | -2,82 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 2,500 | 0,00 % | Bio-Path files to sell 484K shares of common stock for holders | ||
| BIOMEA FUSION | 10,770 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
AURA BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 7,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
